OKO. S. Kozhushnaia

O. S. Kozhushnaia

*This is an algorithmically generated author record based on publicly available information.

O. S. Kozhushnaia has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of markers of hepatitis B, C and HIV infection among patients of pediatric oncohematology departments

    by A. V. Satsuk, G. G. Solopova, S. V. Begunova, E. V. Rozantseva, O. S. Kozhushnaia, P. E. Emelianova, G. A. Novichkova, A. A. Ploskireva, V. G. Akimkin, А. В. Сацук, et al.

    The aim of the study was to conduct a retrospective analysis of the prevalence of markers for hepatitis B (HBV), hepatitis C (HCV), and HIV infection among patients in pediatric onco-hematology departments at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (hereinafter referred to as the Center) between 2013 and 2025, and to compare these findings with general population prevalence rates for chronic HBV, chronic HCV, and HIV infection. Materials and methods. A retrospective analysis was performed on the detection rates of markers for HBV, HCV, and HIV infection among onco-hematology patients aged 0—19 years treated at the Center between 2013 and 2025. A comparative analysis was conducted against the prevalence of these infections in the country's pediatric population during the period from 2013 to 2024. Testing for HBV markers was performed in 17,816 patients, for HCV markers in 17,762 patients, and for HIV infection markers in 17,741 patients. HBV markers were identified via HBsAg and/or HBV DNA testing; HCV markers via anti-HCV and/or HCV RNA testing; and HIV infection via immunoblotting results. Results. The mean detection rates for HBV, HCV, and HIV infection markers were 1.1%, 0.1%, and 0.1%, respectively, of all patients tested. A comparison of the detection rates of HBV, HCV, and HIV markers among pediatric patients in onco-hematology units with the prevalence of these infections in the country's pediatric population revealed rates that were 6, 45, and 3 times higher ( p < 0.001), respectively. Conclusions. Pediatric patients in onco-hematology units constitute a high-risk group for HBV, HCV, and HIV infections.

  • Open Access

    Fusariosis in immunocompromised pediatric patients: results of a single-center study

    by Galina G. Solopova, Nadezhda V. Suvorova, Anastasia O. Vereshchagina, Zhanna V. Markova, Aleksandr D. Voropaev, O. S. Kozhushnaya, A. V. Satsuk, Galina A. Novichkova

    Over the past two decades, the incidence of rare invasive mycoses, including fusariosis, has increased. Fusariosis remains diagnostically challenging and is associated with high mortality. Here, we present the results of a retrospective-prospective single-center study conducted between 01.01.2013 and 01.11.2025 at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The study aimed to evaluate the clinical characteristics, diagnostic performance, and treatment outcomes of immunocompromised children with fusariosis. It included 16 patients (10 males and 6 females), the median age was 11.5 years (range 2.5–16.0). Hematological malignancies were present in 70% of the cases; primary immunodeficiency, aplastic anemia, osteosarcoma, and systemic lupus erythematosus were less common. Fusariosis developed after chemotherapy (n = 9), hematopoietic stem cell transplantation (n = 4), or immunosuppressive therapy (n = 3). The major risk factors included severe neutropenia and corticosteroid use (87.5%). Disseminated disease occurred in 50% of the patients, localized fusariosis was diagnosed in 40% of the patients, and isolated fungemia was reported in one case. The most frequently affected sites were skin/soft tissues (50%), paranasal sinuses (50%), and lungs (43.75%). Parenchymal organs, bones and eyes were involved less often. The main pathogens were Fusarium solani (n = 6) and Fusarium proliferatum (n = 5), followed by Fusarium oxysporum, Fusarium verticilioides, and Fusarium petroliphilum. Seven patients developed invasive fungal co-infections with Aspergillus flavus (n = 4), Rhizopus spp. (n = 1), Scedosporium aurantiacum (n = 1) and Candida glabrata (n = 1) which was associated with increased mortality. First-line therapy included lipid formulations of amphotericin B (81%) and voriconazole (56%); combination therapy was used in 62.5% of the cases. Fourteen patients achieved a rapid partial response (the median time to response was 21 days), which correlated with favorable outcomes: all these patients were cured and had significantly higher overall survival. In the entire cohort, the 6-week survival was 81%, the overall survival was 69%. The study demonstrated the effectiveness of timely diagnosis and specific therapy for invasive fusariosis in the most vulnerable category of immunocompromised children.